{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.5","upperLimit":"72","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"The median PFS will be estimated by Kaplan-Meier method along with 95% confidence interval. The biomarker association with PFS will be assessed by the Kaplan-Meier method, log-rank test, and Cox model.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.\n\nCabozantinib: Given PO\n\nPembrolizumab: Given IV","id":"OG000","title":"Treatment (Pembrolizumab, Cabozantinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration from date of treatment start to the date of objectively documented progression or death due to any cause, whichever status is recorded first, assessed up to 2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}